A total of 69% of patients were chemotherapy naïve, 22% had received adjuvant chemotherapy after primary tumour resection, and 15% had received systemic chemotherapy (+anti-VEGF in three of the cases) for palliative or life-extending care. This evidence concerns the gene VEGFA and neoplasm.